IRE1 signaling exacerbates Alzheimer's disease pathogenesis

Claudia Duran-Aniotz, Victor Hugo Cornejo, Sandra Espinoza, Álvaro O Ardiles, Danilo B Medinas, Claudia Salazar, Andrew Foley, Ivana Gajardo, Peter Thielen, Takao Iwawaki, Wiep Scheper, Claudio Soto, Adrian G Palacios, Jeroen J M Hoozemans, Claudio Hetz

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Altered proteostasis is a salient feature of Alzheimer's disease (AD), highlighting the occurrence of endoplasmic reticulum (ER) stress and abnormal protein aggregation. ER stress triggers the activation of the unfolded protein response (UPR), a signaling pathway that enforces adaptive programs to sustain proteostasis or eliminate terminally damaged cells. IRE1 is an ER-located kinase and endoribonuclease that operates as a major stress transducer, mediating both adaptive and proapoptotic programs under ER stress. IRE1 signaling controls the expression of the transcription factor XBP1, in addition to degrade several RNAs. Importantly, a polymorphism in the XBP1 promoter was suggested as a risk factor to develop AD. Here, we demonstrate a positive correlation between the progression of AD histopathology and the activation of IRE1 in human brain tissue. To define the significance of the UPR to AD, we targeted IRE1 expression in a transgenic mouse model of AD. Despite initial expectations that IRE1 signaling may protect against AD, genetic ablation of the RNase domain of IRE1 in the nervous system significantly reduced amyloid deposition, the content of amyloid β oligomers, and astrocyte activation. IRE1 deficiency fully restored the learning and memory capacity of AD mice, associated with improved synaptic function and improved long-term potentiation (LTP). At the molecular level, IRE1 deletion reduced the expression of amyloid precursor protein (APP) in cortical and hippocampal areas of AD mice. In vitro experiments demonstrated that inhibition of IRE1 downstream signaling reduces APP steady-state levels, associated with its retention at the ER followed by proteasome-mediated degradation. Our findings uncovered an unanticipated role of IRE1 in the pathogenesis of AD, offering a novel target for disease intervention.

Original languageEnglish
Pages (from-to)489-506
Number of pages18
JournalActa Neuropathologica
Volume134
Issue number3
Early online date24 Mar 2017
DOIs
Publication statusPublished - 1 Sep 2017

Cite this

Duran-Aniotz, C., Cornejo, V. H., Espinoza, S., Ardiles, Á. O., Medinas, D. B., Salazar, C., ... Hetz, C. (2017). IRE1 signaling exacerbates Alzheimer's disease pathogenesis. Acta Neuropathologica, 134(3), 489-506. https://doi.org/10.1007/s00401-017-1694-x
Duran-Aniotz, Claudia ; Cornejo, Victor Hugo ; Espinoza, Sandra ; Ardiles, Álvaro O ; Medinas, Danilo B ; Salazar, Claudia ; Foley, Andrew ; Gajardo, Ivana ; Thielen, Peter ; Iwawaki, Takao ; Scheper, Wiep ; Soto, Claudio ; Palacios, Adrian G ; Hoozemans, Jeroen J M ; Hetz, Claudio. / IRE1 signaling exacerbates Alzheimer's disease pathogenesis. In: Acta Neuropathologica. 2017 ; Vol. 134, No. 3. pp. 489-506.
@article{ad71a3f854d04e1480359ade908879af,
title = "IRE1 signaling exacerbates Alzheimer's disease pathogenesis",
abstract = "Altered proteostasis is a salient feature of Alzheimer's disease (AD), highlighting the occurrence of endoplasmic reticulum (ER) stress and abnormal protein aggregation. ER stress triggers the activation of the unfolded protein response (UPR), a signaling pathway that enforces adaptive programs to sustain proteostasis or eliminate terminally damaged cells. IRE1 is an ER-located kinase and endoribonuclease that operates as a major stress transducer, mediating both adaptive and proapoptotic programs under ER stress. IRE1 signaling controls the expression of the transcription factor XBP1, in addition to degrade several RNAs. Importantly, a polymorphism in the XBP1 promoter was suggested as a risk factor to develop AD. Here, we demonstrate a positive correlation between the progression of AD histopathology and the activation of IRE1 in human brain tissue. To define the significance of the UPR to AD, we targeted IRE1 expression in a transgenic mouse model of AD. Despite initial expectations that IRE1 signaling may protect against AD, genetic ablation of the RNase domain of IRE1 in the nervous system significantly reduced amyloid deposition, the content of amyloid β oligomers, and astrocyte activation. IRE1 deficiency fully restored the learning and memory capacity of AD mice, associated with improved synaptic function and improved long-term potentiation (LTP). At the molecular level, IRE1 deletion reduced the expression of amyloid precursor protein (APP) in cortical and hippocampal areas of AD mice. In vitro experiments demonstrated that inhibition of IRE1 downstream signaling reduces APP steady-state levels, associated with its retention at the ER followed by proteasome-mediated degradation. Our findings uncovered an unanticipated role of IRE1 in the pathogenesis of AD, offering a novel target for disease intervention.",
keywords = "Journal Article",
author = "Claudia Duran-Aniotz and Cornejo, {Victor Hugo} and Sandra Espinoza and Ardiles, {{\'A}lvaro O} and Medinas, {Danilo B} and Claudia Salazar and Andrew Foley and Ivana Gajardo and Peter Thielen and Takao Iwawaki and Wiep Scheper and Claudio Soto and Palacios, {Adrian G} and Hoozemans, {Jeroen J M} and Claudio Hetz",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s00401-017-1694-x",
language = "English",
volume = "134",
pages = "489--506",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "3",

}

Duran-Aniotz, C, Cornejo, VH, Espinoza, S, Ardiles, ÁO, Medinas, DB, Salazar, C, Foley, A, Gajardo, I, Thielen, P, Iwawaki, T, Scheper, W, Soto, C, Palacios, AG, Hoozemans, JJM & Hetz, C 2017, 'IRE1 signaling exacerbates Alzheimer's disease pathogenesis' Acta Neuropathologica, vol. 134, no. 3, pp. 489-506. https://doi.org/10.1007/s00401-017-1694-x

IRE1 signaling exacerbates Alzheimer's disease pathogenesis. / Duran-Aniotz, Claudia; Cornejo, Victor Hugo; Espinoza, Sandra; Ardiles, Álvaro O; Medinas, Danilo B; Salazar, Claudia; Foley, Andrew; Gajardo, Ivana; Thielen, Peter; Iwawaki, Takao; Scheper, Wiep; Soto, Claudio; Palacios, Adrian G; Hoozemans, Jeroen J M; Hetz, Claudio.

In: Acta Neuropathologica, Vol. 134, No. 3, 01.09.2017, p. 489-506.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - IRE1 signaling exacerbates Alzheimer's disease pathogenesis

AU - Duran-Aniotz, Claudia

AU - Cornejo, Victor Hugo

AU - Espinoza, Sandra

AU - Ardiles, Álvaro O

AU - Medinas, Danilo B

AU - Salazar, Claudia

AU - Foley, Andrew

AU - Gajardo, Ivana

AU - Thielen, Peter

AU - Iwawaki, Takao

AU - Scheper, Wiep

AU - Soto, Claudio

AU - Palacios, Adrian G

AU - Hoozemans, Jeroen J M

AU - Hetz, Claudio

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Altered proteostasis is a salient feature of Alzheimer's disease (AD), highlighting the occurrence of endoplasmic reticulum (ER) stress and abnormal protein aggregation. ER stress triggers the activation of the unfolded protein response (UPR), a signaling pathway that enforces adaptive programs to sustain proteostasis or eliminate terminally damaged cells. IRE1 is an ER-located kinase and endoribonuclease that operates as a major stress transducer, mediating both adaptive and proapoptotic programs under ER stress. IRE1 signaling controls the expression of the transcription factor XBP1, in addition to degrade several RNAs. Importantly, a polymorphism in the XBP1 promoter was suggested as a risk factor to develop AD. Here, we demonstrate a positive correlation between the progression of AD histopathology and the activation of IRE1 in human brain tissue. To define the significance of the UPR to AD, we targeted IRE1 expression in a transgenic mouse model of AD. Despite initial expectations that IRE1 signaling may protect against AD, genetic ablation of the RNase domain of IRE1 in the nervous system significantly reduced amyloid deposition, the content of amyloid β oligomers, and astrocyte activation. IRE1 deficiency fully restored the learning and memory capacity of AD mice, associated with improved synaptic function and improved long-term potentiation (LTP). At the molecular level, IRE1 deletion reduced the expression of amyloid precursor protein (APP) in cortical and hippocampal areas of AD mice. In vitro experiments demonstrated that inhibition of IRE1 downstream signaling reduces APP steady-state levels, associated with its retention at the ER followed by proteasome-mediated degradation. Our findings uncovered an unanticipated role of IRE1 in the pathogenesis of AD, offering a novel target for disease intervention.

AB - Altered proteostasis is a salient feature of Alzheimer's disease (AD), highlighting the occurrence of endoplasmic reticulum (ER) stress and abnormal protein aggregation. ER stress triggers the activation of the unfolded protein response (UPR), a signaling pathway that enforces adaptive programs to sustain proteostasis or eliminate terminally damaged cells. IRE1 is an ER-located kinase and endoribonuclease that operates as a major stress transducer, mediating both adaptive and proapoptotic programs under ER stress. IRE1 signaling controls the expression of the transcription factor XBP1, in addition to degrade several RNAs. Importantly, a polymorphism in the XBP1 promoter was suggested as a risk factor to develop AD. Here, we demonstrate a positive correlation between the progression of AD histopathology and the activation of IRE1 in human brain tissue. To define the significance of the UPR to AD, we targeted IRE1 expression in a transgenic mouse model of AD. Despite initial expectations that IRE1 signaling may protect against AD, genetic ablation of the RNase domain of IRE1 in the nervous system significantly reduced amyloid deposition, the content of amyloid β oligomers, and astrocyte activation. IRE1 deficiency fully restored the learning and memory capacity of AD mice, associated with improved synaptic function and improved long-term potentiation (LTP). At the molecular level, IRE1 deletion reduced the expression of amyloid precursor protein (APP) in cortical and hippocampal areas of AD mice. In vitro experiments demonstrated that inhibition of IRE1 downstream signaling reduces APP steady-state levels, associated with its retention at the ER followed by proteasome-mediated degradation. Our findings uncovered an unanticipated role of IRE1 in the pathogenesis of AD, offering a novel target for disease intervention.

KW - Journal Article

U2 - 10.1007/s00401-017-1694-x

DO - 10.1007/s00401-017-1694-x

M3 - Article

VL - 134

SP - 489

EP - 506

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 3

ER -

Duran-Aniotz C, Cornejo VH, Espinoza S, Ardiles ÁO, Medinas DB, Salazar C et al. IRE1 signaling exacerbates Alzheimer's disease pathogenesis. Acta Neuropathologica. 2017 Sep 1;134(3):489-506. https://doi.org/10.1007/s00401-017-1694-x